Pfizer's Cancer Drug Ibrance Combo Therapy Extends Median Progression-Free Survival By Over 15 Months In certain Of Breast Cancer Patients
Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) announced results from the Phase 3 PATINA trial. The trial ...
Study finds increased survival with nivolumab plus ipilimumab vs. chemo for metastatic colorectal cancer
For patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer ...
The American Journal of Managed Care3d
Cilta-cel Leads to Prolonged Progression-Free Survival in Multiple Myeloma
Yi Lin, MD, PhD, hematologist and oncologist, Mayo Clinic, discusses the efficacy of ciltacabtagene autoleucel (cilta-cel) chimeric antigen receptor T-cell therapy vs standard treatments for patients ...
Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer
Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced ...
Renal & Urology News2d
Survival Up With Nivolumab + Ipilimumab Versus Chemo for Metastatic CRC
Findings seen in patients with microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancer ...
Next-generation treatment protects against progression in some patients with advanced breast cancer
Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free ...
AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients
AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...
Medscape6d
IVIG Prophylaxis in Multiple Myeloma Cuts Infections, Boosts Survival
IVIG prophylaxis led to improvements in infection-free survival as well as progression free and overall survival in patients ...
IN8bio (NASDAQ:INAB) Reports Continued Progression-Free Survival in Phase 1 Trial at ASH Annual Meeting
IN8bio, Inc., a clinical-stage biopharmaceutical company focusing on innovative gamma-delta T cell therapies, recently shared updated data on December 10, 2024. This data demonstrated sustained ...
Too Old to Operate8d
Cadonilimab plus chemotherapy improves survival in recurrent or metastatic cervical cancer
Cadonilimab plus chemotherapy significantly improved progression-free survival in patients with persistent, recurrent, or ...
PharmiWeb5d
DARZALEX® (daratumumab) SC-based regimens improve…
Janssen-Cilag International NV, a Johnson & Johnson company, announced data highlighting that DARZALEX® (daratumumab) subcutaneous (SC)-based regimens improve overall and sustained minimal residual ...